MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Stock Down 2.7 %
Shares of NASDAQ:MDWD opened at $1.80 on Tuesday. MediWound has a fifty-two week low of $1.21 and a fifty-two week high of $4.01. The firm has a 50-day simple moving average of $1.71 and a 200 day simple moving average of $1.95.
MediWound (NASDAQ:MDWD - Get Rating) last announced its quarterly earnings data on Tuesday, May 17th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). MediWound had a negative net margin of 64.01% and a negative return on equity of 3,540.43%. The business had revenue of $4.41 million for the quarter, compared to the consensus estimate of $4.35 million. During the same period in the prior year, the company earned ($0.10) EPS. As a group, analysts expect that MediWound will post -0.37 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently issued reports on MDWD shares. Wells Fargo & Company lifted their price target on shares of MediWound to $8.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 18th. Oppenheimer reaffirmed an "outperform" rating and set a $7.00 price target on shares of MediWound in a research note on Monday, July 18th. Finally, StockNews.com started coverage on shares of MediWound in a research report on Tuesday. They issued a "sell" rating for the company. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, MediWound currently has an average rating of "Moderate Buy" and a consensus price target of $7.13.